Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_assertion type Assertion NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_head.
- NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_assertion description "[To assess impact on health outcomes and healthcare expenditures of adopting a 21-gene assay for women with early-stage, minimally node-positive, estrogen receptor-positive (N (1-3)/ER) HER2-negative breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_provenance.
- NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_assertion evidence source_evidence_literature NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_provenance.
- NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_assertion SIO_000772 21819166 NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_provenance.
- NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_assertion wasDerivedFrom befree-2016 NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_provenance.
- NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_assertion wasGeneratedBy ECO_0000203 NP914991.RAIlxjloELSz8KS5xf51Zc1kpxNrGtqEkGFe4W4akxVvM130_provenance.